



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 60859

**Title:** Evaluation of a five gene signature associated with stromal infiltration for diffuse large B-cell lymphoma

**Reviewer's code:** 02544757

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-11-16

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2020-12-30 15:15

**Reviewer performed review:** 2021-01-12 08:20

**Review time:** 12 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

Through analyzing the e GSE60 dataset in DLBCL and using principal components analysis (PCA) plot, the authors identified five genes were closely associated with tumor stage and stromal infiltration in DLBCL. The author also found two genes, FN1 and SPARC, cooperatively expressed in DLBCL, which may be novel therapeutic targets for DLBCL. Although the current manuscript showed five genes may be associated with the development of DLBCL, there are many issues should be addressed. My comments are in the following 1. The author first used the GSE60 dataset to evaluate different gene expressions in DLBCL and normal tissue. Do the differentially expressed genes in DLBCL could further be divided into germinal center (GC) B-like or activated B-like DLBCL? I think this is important because the gene expressions in these two groups are different. 2. The author used the STRING to identify five hub overexpressed genes in DLBCL. The legends of Figure 2B-F are needed to describe the data validation from TCGA dataset. 3. The author studied the five hub genes that were higher expressed in late stages than in early stages. The FN1 gene expression had a stage-dependent increase. Are there any significant differences (P value) when comparing stage 2, 3 or 4 to stage 4? In addition, is FN1 gene expression also associated with high IPI scores in DLBCL? 4. In figure 5-8, the overexpression of 5 genes had different Spearman's relationship to stromal score or CAF. It is better to describe high, moderate, or low correlations of every genes, respectively. In addition, it is better to arrange other experiments to validate these correlations.